Caroline Robert

机构：Université Paris-Sud, Inserm, Université Paris-Saclay, Institut Gustave Roussy · ORCID：0000-0002-9493-0238

发表论文 1472 篇 · 总被引 161600 次 · h-index 159

代表论文

• Neoadjuvant PD-1 and LAG-3-targeting bispecific antibody and other immune checkpoint inhibitor combinations in resectable melanoma: the randomized phase 1b/2 Morpheus-Melanoma trial (2025 · Nature Medicine · 被引 19)
• International real-world study of combination immunotherapy sequences in metastatic melanoma (2025 · Journal for ImmunoTherapy of Cancer · 被引 1)
• 1684TiP Intismeran autogene (V940/mRNA-4157) + pembrolizumab versus pembrolizumab alone as first-line therapy for advanced melanoma: The phase II INTerpath-012 study (2025 · Annals of Oncology · 被引 1)
• Collagenous colitis in patients treated for cancer: role of immune checkpoint inhibitors. Clinical, histological and immunological features in 15 cases (2025 · Histopathology · 被引 1)
• COMBI-I: Long-Term Overall Survival With Spartalizumab Plus Dabrafenib and Trametinib in BRAF V600–Mutant Advanced Melanoma (2026 · Journal of Clinical Oncology)
• Neoadjuvant Intralesional Daromun (L19IL2/L19TNF) in Resectable Locally Advanced Melanoma: An Update on the Efficacy and Safety Results of the PIVOTAL Phase III Trial (2026 · Journal of Clinical Oncology)